Interim Assessement Report
The EMA review was started by the Agency’s Committee for Medicinal Products for Human Use (CHMP) to support decision-making by health authorities. This first interim report includes information on seven experimental medicines intended for the treatment of people infecte...d with the Ebola virus:
BCX4430 (Biocryst);
Brincidofovir (Chimerix);
Favipiravir (Fujifilm Corporation/Toyama);
TKM-100802 (Tekmira);
AVI-7537 (Sarepta);
ZMapp (Leafbio Inc.);
Anti-Ebola F(ab’)2 (Fab’entech).
The amount of information available for the seven treatments is highly variable. For some compounds there is no data from use in human subjects available. A small number of treatments have been administered to patients in the current Ebola outbreak as compassionate use. Finally, there are also medicines included in this review that have already been studied in humans, albeit for the treatment of other viral diseases.
more
The interventions summarized in this guide are intended to lower the risk of delivery and post-partum complications for both the mother and the newborn, particularly the risk of postpartum haemorrhage and infections, and improve the immediate care of premature babies. The recommendations are also in...tended to minimize the exposure of health care providersto blood and bodily fluids that could transmit Ebola
more
This publication gives a broad vision of what a comprehensive approach to cervical cancer prevention and control means. In particular, it outlines the complementary strategies for comprehensive cervical cancer prevention and control, and highlights the neners. This new guide updates the 2006 edition... and includes the recent promising deve
ed for collaboration across programmes, organizations and partl-
opments in technologies and strategies that can address the gaps between the needs for and availability of services for cervical cancer prevention and control.
more
BMC Medicine 2014, 12:196
http://www.biomedcentral.com/1741-7015/12/196
Desk Review and Recommendations for Private Sector Engagement
Infectious Diseases of Poverty 2014, 3:42
http://www.idpjournal.com/content/3/1/42
Eur Respir J 2014; 43: 24–35 | DOI: 10.1183/09031936.00113413
Review
S Afr Med J 2014;104(3):174-177. DOI: 10.7196/SAMJ.7968
Research
BMJ 2014;349:g4643 doi: 10.1136/bmj.g4643 (Published 5 August 2014), 1-11
The report focuses on antibacterial resistance (ABR) in common bacterial pathogens. There is a major gap in knowledge about the magnitude of this problem. Antimicrobial resistance (AMR) threatens the effective revention and treatment of an ever-increasing range of infections caused by bacteria, para...sites, viruses and fungi. This WHO report, produced in collaboration with Member States and other partners, provides for the first time, as accurate a picture as is presently possible of the magnitude of AMR and the current state of surveillance globally. It examines the information on AMR, in particular antibacterial resistance (ABR), at country level worldwide.
more
"Patient decontamination principles are set forth here from a strategic perspective, rather than a tactical
one. The principles are meant to guide, but not specify, operational practices. The guidance is evidencebased
to the extent possible and the supporting evidence is documented and briefly dis...cussed."
more
A tutorial for trainers in healthcare settings
Version 2: 2 Dec 2014
"The document focuses on an extended set of PPE components, which includes goggles, respirators, gloves,
coveralls and footwear. Used properly, these PPE components can provide effective protection even from airborne
transmissi...on. The presented PPE components can be used in a variety of settings and also in different
combinations. At the same time, the tutorial shall encourage trainers and users to understand the rationales behind
the different approaches. "
more
It provides selected illustrations and photographs of congenital anomalies that are severe enough to have a high probability of being captured during the first few days following birth